FOOD AND DRUG ADMINISTRATION
Center for Drug Evaluation and Research
ANTI-INFECTIVE DRUGS ADVISORY COMMITTEE (AIDAC) MEETING
QUESTIONS TO THE COMMITTEE
February 19, 2002
Holiday Inn, Two Montgomery Village Avenue, Gaithersburg, MD
Topic: Proposed approach for selection of delta in non-inferiority (equivalence) clinical trials
B. 3 arm trials: placebo, new drug, approved drug
C. dose-response trials or other superiority trial design
As time permits, discuss these trial designs for other indications (e.g. acute otitis media, sinusitis).
2. Please discuss the implication of choice of deltas in clinical trials for serious infections. Please consider in your discussion the efficacy of a new drug compared to currently available therapies for the indication (e.g. HAP, meningitis).
3. Please discuss what other factors/characteristics of a drug product, other than primary confidence interval results, could be included in the risk-benefit analysis supporting an FDA regulatory decision.
Please include the following in your discussion: